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Abstract
Aims/hypothesis The aim of this analysis was to quantify
the relationship between the frequency of hypoglycaemia
and various glucose cut-off points for the definition of
hypoglycaemia, within a range of HbA1c strata.
Methods Data from two trials examining insulin glargine dose
titration in 12,837 type 2 diabetic participants starting insulin
therapy were combined. Curves for hypoglycaemia frequency
plotted against endpoint HbA1c level were constructed, using
a range of glucose cut-off points for hypoglycaemia.
Results During the 12-week study period, 3,912 patients
recorded 21,592 hypoglycaemic episodes, comprising 242
severe, 8,871 symptomatic and 12,479 asymptomatic events,
corresponding to hypoglycaemia event rates of 0.10, 3.8 and
5.3 events per patient year. Increasing the hypoglycaemia cut-
off point from, for instance, <3.1 to <3.9 mmol/l more than
doubled the percentage of affected patients, e.g. from 17.7 to
43.3% at HbA1c 7.0–7.2%. At higher hypoglycaemia cut-off
points the proportion of patients having only asymptomatic
hypoglycaemia increased, e.g. from 30.7% at <3.1 mmol/l to
61.7% of patients at a cut-off point of <3.9 mmol/l. In
sensitivity analysis, 121 of 1,756 patients with at least one
self-monitored blood glucose value <3.1 mmol/l experienced
severe hypoglycaemia, compared with 149 of 3,912 patients
with a self-monitored blood glucose level of <3.9 mmol/l.
Thus, to identify 28 more patients with severe hypoglycae-
mia, the number of patients experiencing only non-severe
hypoglycaemia more than doubled.
Conclusions/interpretation The glucose cut-off point defining
hypoglycaemia greatly affects the reported frequency of
hypoglycaemia. When hypoglycaemia is to be defined by a
predetermined glucose level, to have clinical relevance the
cut-off should be set at a lower level than the threshold of
3.9 mmol/l proposed by the American Diabetes Association.
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Abbreviations
ADA American Diabetes Association
GOAL A1C Glycemic Optimization with Algorithms and
Labs at Point of Care A1C
GOT Glycemic Optimization Treatment
SMBG self-monitored blood glucose
Introduction
Despite its importance, a uniform definition of hypogly-
caemia is conspicuously absent when looking at the
diabetes literature, particularly when considering rando-
mised controlled trials of glucose-lowering therapies. In
2005 the American Diabetes Association (ADA) sought to
remedy this situation by defining hypoglycaemia as an
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event accompanied by a measured plasma glucose concentra-
tion ≤3.9 mmol/l. This plasma glucose threshold was chosen
because in non-diabetic people glucose counter-regulation is
activated at this level and antecedent glucose concentrations of
≤3.9 mmol/l reduce counter-regulatory responses to subse-
quent hypoglycaemia [1].
Obviously, standardised reporting of hypoglycaemia is
desirable, but it has been argued that defining hypoglycaemia
as any glucose value below 4.0 mmol/l may lead to
overestimation of the frequency of (clinically significant)
hypoglycaemia [2]. Plasma glucose falls below this level in
health and exposure to glucose levels of 3.5–4.0 mmol/l is
likely to be of little clinical significance [2].
The aim of this analysis was to quantify the relationship
between the frequency of hypoglycaemia and various glucose
cut-off points for the definition of hypoglycaemia, within a
range of HbA1c strata.
Methods
Included studies Data from two 24-week randomised trials,
examining various methods of insulin glargine dose titration
in adults with type 2 diabetes uncontrolled by oral glucose-
lowering agents and requiring insulin therapy, were combined
(the Glycemic Optimization with Algorithms and Labs at
Point of Care A1C [GOAL A1C] trial [3] and the Glycemic
Optimization Treatment [GOT] study [clinicaltrials.gov ID
no. NCT00552370]). In both studies insulin glargine was
administered once daily at bedtime and titrated weekly, based
on fasting self-monitored blood glucose (SMBG) concen-
trations, measured once daily. Participants were informed
about the general symptoms of hypoglycaemia (sweating,
drowsiness, etc.) and were instructed to also measure their
blood glucose any time they experienced such symptoms.
HbA1c was measured by central laboratory analysis (aligned
with the Diabetes Control and Complications Trial) every
6 weeks. Hypoglycaemia was defined as an SMBG level
<3.9 mmol/l. If participants indicated that they had experi-
enced symptoms typical of hypoglycaemia the event was
classified as symptomatic. Hypoglycaemic events were
classified as severe if the patient required assistance and (1)
there was prompt response to treatment, or (2) the SMBG
level was <2.0 mmol/l.
Method To minimise the destabilising effects associated with
treatment intensification, the analysis period was defined as the
final 12 weeks of the included trials. Study participants without
an endpoint HbA1c measurement (week 24, or last observa-
tion carried forward obtained after week 12) were excluded
(n=2,778). HbA1c was categorised using an arbitrary cate-
gory width of 0.3% and HbA1c categories ≤5.1% and >11.7%
were excluded because of limited patient numbers (n=93).
The analysis was based on all daily fasting glucose measure-
ments and any additional measurements with an SMBG
concentration <3.9 mmol/l, i.e. all symptomatic and asymp-
tomatic hypoglycaemic episodes with blood glucose below
this level were included. Severe hypoglycaemic episodes
were analysed separately. Hypoglycaemia frequency was
plotted against endpoint HbA1c category using a range of
predefined glucose cut-off points for hypoglycaemia. Both
the proportions of patients experiencing at least one episode
of hypoglycaemia and hypoglycaemia event rates were
examined. A sensitivity analysis was performed to compare
the sensitivity and specificity of a range of hypoglycaemia
cut-off points for identifying patients experiencing severe
hypoglycaemia.
Results
The analysis population consisted of 9,966 patients, with
mean age 56.4 years, BMI 34.5 kg/m2, diabetes duration
8.5 years and baseline HbA1c 9.0% (see Electronic supple-
mentary material [ESM] Table 1). Of these participants,
3,912 had 21,592 SMBG confirmed hypoglycaemic epi-
sodes, including 242 severe events. Of the 21,350 non-severe
hypoglycaemic episodes, 8,871 (41.6%) were symptomatic
and 12,479 (58.4%) asymptomatic. Hypoglycaemia event
rates were 3.8, 5.3 and 0.10 events per patient year for
symptomatic, asymptomatic and severe hypoglycaemia
respectively.
Figure 1 shows that, compared with a lower hypogly-
caemia cut-off point, such as <3.1 mmol/l, the ADA
definition of 3.9 mmol/l more than doubled the percentage
of affected patients across a wide range of HbA1c strata, e.g.
from 17.7 to 43.3% at HbA1c of about 7%. Considering
event rates, the discrepancy was even larger, with 0.3 vs 1.3
events per 100 patient days, as the number of events per
patient also increased with higher cut-offs (ESM Fig. 1). At
higher hypoglycaemia cut-off points the proportion of
patients having only asymptomatic hypoglycaemia, i.e.
without any symptomatic events, increased from (for
instance) 30.7% at a cut-off of <3.1 mmol/l to 61.7% at a
cut-off of <3.9 mmol/l (Fig. 2).
Of all patients, 1.5% (n=149) recorded a severe
hypoglycaemic episode. This percentage of affected
patients was consistent across HbA1c strata up to an HbA1c
level of 9.9%, above which no participant experienced
severe hypoglycaemia. In sensitivity analysis, again taking
the 3.1 mmol/l cut-off point as an example, 121 of 1,756
patients with at least one SMBG <3.1 mmol/l (i.e. including
all non-severe and severe hypoglycaemic events with
SMBG <3.1 mmol/l) experienced severe hypoglycaemia,
compared with 149 of 3,912 patients with at least one
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SMBG <3.9 mmol/l. Thus, to identify 28 more patients with
severe hypoglycaemia, the number of patients experiencing
only non-severe hypoglycaemia more than doubled. Similarly,
82.2% (199/242) of the severe hypoglycaemic episodes
occurred in patients who had had a SMBG <3.1 mmol/l at
some other time during the 12 weeks, and 97.5% (236/242) in
patients who had had a SMBG <3.7 mmol/l.
Discussion
Our main finding was that, in a large cohort of type 2 diabetic
patients starting insulin therapy, higher cut-off points for the
definition of hypoglycaemia considerably increased the
reported frequency of hypoglycaemia, and particularly that
of asymptomatic hypoglycaemia. Higher cut-offs identified
more patients having severe hypoglycaemia, but this was at
the expense of the specificity, i.e. a very large number of
patients that did not experience severe hypoglycaemic
episodes were also labelled as ‘at risk’.
Because we combined the data of two large clinical trials,
our analysis was based on a substantial number of hypogly-
caemic episodes that had been systematically recorded.
Nevertheless, hypoglycaemia may have been under-reported
as in both trials investigators depended on the patients
bringing their diaries to the site visits. Moreover, hypoglycae-
mia had been defined as an event confirmed by an SMBG
value <3.9 mmol/l, so we did not include episodes with
symptoms typical of hypoglycaemia but without glucose
determinations. Third, as the study population had only just
started insulin and thus many were hypoglycaemia-naive,
some hypoglycaemic episodes may not have been recognised
as such. However, this under-recognition was minimised by
repeated discussion of hypoglycaemia symptomatology dur-
ing the clinic visits. Finally, the presence of hypoglycaemia
unawareness, which was not formally assessed, could have
confounded our results because this is associated with an
increased frequency of (severe) hypoglycaemia but fewer self-
reported events [4, 5]. However, hypoglycaemia unawareness
is rare in patients with type 2 diabetes recently initiated on
basal insulin therapy.
The proportions of affected patients and hypoglycaemia
event rates we found were higher than those reported for
newly diagnosed participants in the UK Prospective Diabetes
Study [6], but equal to those reported for type 2 diabetic
patients newly started on insulin (<2 years) in a recent
observational study [7]. With regard to severe hypoglycae-
mia, population-based and retrospective studies of insulin-
treated individuals with type 2 diabetes reported higher event
rates [8–10]. However, our study population had just started
insulin, and the frequency of hypoglycaemia and the
prevalence of hypoglycaemia unawareness are much greater
in people with type 1 diabetes and type 2 diabetic patients
with a longer duration of insulin treatment. It might be useful
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Fig. 2 Proportion of patients experiencing only asymptomatic non-
severe hypoglycaemic episodes during the 12-week analysis period
(black bars) vs proportion of patients also experiencing symptomatic
hypoglycaemic episodes (white bars), for a range of predefined


































































































































































Fig. 1 Proportion of patients
experiencing at least one non-
severe hypoglycaemic episode
during the 12-week analysis
period for a range of predefined
glucose cut-off points for the
definition of hypoglycaemia,
plotted against endpoint HbA1c
categories
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as well. Although it may prove necessary to use different
glucose cut-off points defining hypoglycaemia for different
patient populations, we expect that the demonstrated impact
of the hypoglycaemia cut-off on the reported frequencies of
hypoglycaemia can be largely generalised to other patient
groups.
According to our analysis, more than 40% of type 2
diabetic patients starting insulin therapy experienced hypo-
glycaemia when the ADA definition was used. These
events were usually asymptomatic and of limited use in
identifying patients at risk of severe hypoglycaemia. Since
the clinical significance of exposure to glucose concentra-
tions of 3.5–4.0 mmol/l is probably minor, and as strict
avoidance of such glucose levels is likely to have an adverse
effect on average glycaemia, we propose a hypoglycaemia
definition that is lower than the cut-off point of 3.9 mmol/l,
particularly in individuals with type 2 diabetes who have just
started insulin treatment.
Acknowledgements This study was supported financially by sanofi
aventis.
Duality of interest S. G. H. A. Swinnen is employed by the
Department of Internal Medicine of the Academic Medical Centre,
Amsterdam, the Netherlands, partly through funding from Novo Nordisk
and sanofi aventis for the conduct of clinical trials. P. Mullins has received
research support from sanofi aventis. M. Miller is employed as Senior
Manager Statistics at sanofi aventis. J. B. L. Hoekstra has received
honoraria for consultancy work from Novartis and sanofi aventis.
F. Holleman is currently principal investigator for a multinational trial
sponsored by sanofi aventis, has served on advisory boards for sanofi
aventis and received a study grant from Novo Nordisk.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. American Diabetes AssociationWorkgroup on Hypoglycemia (2005)
Defining and reporting hypoglycemia in diabetes: a report from the
American Diabetes Association Workgroup on Hypoglycemia.
Diabetes Care 28:1245–1249
2. Amiel SA, Dixon T, Mann R, Jameson K (2008) Hypoglycaemia
in type 2 diabetes. Diabet Med 25:245–254
3. Kennedy L, Herman WH, Strange P, Harris A, for the GOAL A1C
Team (2006) Impact of active versus usual algorithmic titration of
basal insulin and point-of-care versus laboratory measurement of
HbA1c on glycemic control in patients with type 2 diabetes: The
Glycemic Optimization with Algorithms and Labs at Point of Care
(GOAL A1C) trial. Diabetes Care 29:1–8
4. Gold AE, MacLeod KM, Frier BM (1994) Frequency of severe
hypoglycemia in patients with type I diabetes with impaired
awareness of hypoglycemia. Diabetes Care 17:697–703
5. Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T (2004)
Assessment of hypoglycaemia awareness using continuous glucose
monitoring. Diabet Med 21:487–490
6. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive
blood-glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). Lancet 352:837–853
7. UK Hypoglycaemia Study Group (2007) Risk of hypoglycaemia
in types 1 and 2 diabetes: effects of treatment modalities and their
duration. Diabetologia 50:1140–1114
8. Donnelly LA, Morris AD, Frier BM et al (2005) Frequency and
predictors of hypoglycaemia in type 1 and insulin-treated type 2
diabetes: a population-based study. Diabet Med 22:749–755
9. MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and
morbidity of severe hypoglycaemia in insulin-treated diabetic
patients. Diabet Med 10:238–245
10. Henderson JN, Allen KV, Deary IJ, Frier BM (2003) Hypoglycaemia
in insulin-treated type 2 diabetes: frequency, symptoms and impaired
awareness. Diabet Med 20:1016–1021
Diabetologia (2009) 52:38–41 41
